Safety and Tolerability

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

4TEEN4 Pharmaceuticals
4TEEN4 PharmaceuticalsGermany - Hennigsdorf
1 program
1
AK1967Phase 11 trial
Active Trials
NCT06331884CompletedEst. Sep 2024
Alumis
AlumisSOUTH SAN FRANCISCO, CA
1 program
1
Experimental drug: ESK-001Phase 11 trial
Active Trials
NCT05431634Completed49Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
4TEEN4 PharmaceuticalsAK1967
AlumisExperimental drug: ESK-001

Clinical Trials (2)

Total enrollment: 49 patients across 2 trials

Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)

Start: Mar 2024Est. completion: Sep 2024
Phase 1Completed
NCT05431634AlumisExperimental drug: ESK-001

Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

Start: May 2022Est. completion: Dec 202249 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space